Taysha Gene Therapies

TSHA13F as of Jun 30, 2026 · next update ~Nov 14

Limited coverage

Only 1 fund we track owns this stock, so quarterly sentiment and aggregates may be sparse.

Who's buying TSHA

Top funds mostly added to Taysha Gene Therapies in Q2 (Apr⁠–⁠Jun)

Buying:

Funds1InsidersCongress

Top funds
1 of 1 bought more, 0 sold some. Largest: Polen Capital Management, $3.3M (0% of its portfolio).
Insiders
No buys, 8 sales in 12 months.
Congress
No trades disclosed in the last 12 months.

1 fund$3.3M held0.0% avg. weightQ2: 1 bought / 0 sold

13F reports are a snapshot as of Jun 30, 2026; funds may have traded since. Insiders often sell for personal reasons (taxes, diversification, planned sales).

Share price · market data, not from 13F reports

Q2 2026

Insider trades (Form 4)

Last 2 years · 12 filings

Net buying$9.68M

Date	Insider	Type	Shares	Price	Value
Jul 10, 2026	Sukumar Nagendran President	Sold	200,000	$6.24	$1.25M
Apr 10, 2026	Sukumar Nagendran President	Sold	200,000	$4.46	$892K
Feb 4, 2026	Kamran Alam CFO	Sold	1,655	$4.52	$7K
Jan 23, 2026	Sukumar Nagendran President	Sold	116,050	$4.72	$547K
Jan 23, 2026	Sean P. Nolan CEO	Sold	178,101	$4.72	$840K
Jan 23, 2026	Kamran Alam CFO	Sold	102,817	$4.72	$485K
Jan 12, 2026	Sukumar Nagendran President	Sold	200,000	$4.71	$942K
Nov 28, 2025	Sukumar Nagendran President	Sold	370,172	$4.58	$1.70M
Sep 10, 2025	Sukumar Nagendran President	Sold	200,000	$3.23	$646K
Aug 21, 2025	Sukumar Nagendran President	Sold	57,054	$2.85	$163K
Aug 21, 2025	Kamran Alam CFO	Sold	54,491	$2.85	$155K
May 30, 2025	Paul B Manning 10% Owner	Bought	750,000	$2.75	$2.06M